Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service peripheral nerve stimulation & intrathecal pumps cases in Nevada: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 11% on average (174 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 3 | 325 | 42% |
| 2020 | 2 | 219 | 45% |
| 2021 | 4 | 310 | 48% |
| 2022 | 2 | 231 | 51% |
| 2023 | 5 | 215 | 54% |
| 2024 | 2 | 316 | 56% |
| 2025 from claims | – | 439 355–515 | 57% |
| 2026 forecast | – | 460 360–578 | 57% |
| 2027 forecast | – | 480 356–635 | 58% |
| 2028 forecast | – | 502 355–692 | 58% |
| 2029 forecast | – | 524 356–751 | 59% |
| 2030 forecast | – | 547 358–811 | 60% |
PNS lead and generator, intrathecal pump and catheter. Professional codes (what the surgeon bills): CPT 64555, 64590, 62362, 62350.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Nevada; 2 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 29% hospital outpatient, 71% surgery center. The share outside the hospital has moved +24 pts since 2019, so more of this market is decided in surgery centers and offices each year.
| Forecast, Medicare FFS | Hospital outpatient | Surgery center |
|---|---|---|
| 2026 · ~460 | ~120 | ~340 |
| 2027 · ~480 | ~120 | ~360 |
| 2028 · ~500 | ~120 | ~380 |
The forecast’s cases at the projected mix.
If the trend since 2022 holds, slowing as it goes, by 2028: surgery center about 75% (71% in 2025), hospital outpatient about 25% (29% in 2025). More of these cases each year are decided in surgery centers, where the surgeons often own the center and weigh price and turnaround.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 35 | 2,932+9.5%/yr | +9.5%/yr | 0.8 | 78% | 6,310 in 2030+14%/yr |
| Arizona | 23 | 1,632+19%/yr | +19%/yr | 2.0 | 90% | 3,070 in 2030+11%/yr |
| Washington | 8 | 573+7.4%/yr | +7.4%/yr | 0.7 | 55% | 1,090 in 2030+11%/yr |
| Colorado | 10 | 515+13%/yr | +13%/yr | 1.0 | 55% | 1,080 in 2030+13%/yr |
| Idaho | 4 | 403+11%/yr | +11%/yr | 1.8 | 20% | 790 in 2030+12%/yr |
| Oregon | 4 | 325+4.4%/yr | +4.4%/yr | 0.7 | 91% | 1,740 in 2030+32%/yr |
| Utah | 1 | 290+14%/yr | +14%/yr | 1.2 | 60% | 570 in 2030+12%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Radiofrequency ablation (facet, genicular, basivertebral) | 54 | 3,899−4.7%/yr | −4.7%/yr | 12.91.3× | 98% | 4,350 in 2030+1.8%/yr |
| Spinal cord & DRG stimulation | 6 | 353−6%/yr | −6%/yr | 1.12.0× | 95% | 380 in 2030+1%/yr |
Peripheral nerve stimulation & intrathecal pumps in every state, and its device makers · Every procedure market in Nevada · Every state · Compare with California
Boston Scientific leads with 52% of company spending on these surgeons in 2025, +12 pts on 2024.
In 2025, 7 companies reported engagement with Nevada’s surgeons worth $44K in consulting, speaking, meals and travel tied to these products, about $22K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 13 clearances and approvals in the category, 2 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.